Cell Death Dis:LINC01559 activates the PI3K/AKT signaling path path, which promotes the development of stomach cancer.

Gastric cancer (GC) is a well-known gastrointestinal tumor with a high incidence of the disease worldwide.
GC-induced factors, including alcoholism, dieting, unscientific eating habits and genetic factors.
traditional treatments for the disease include chemotherapy and surgery, molecular targeting strategies have received increasing attention in recent years.
the types and efficacy of targeted drugs currently used in GC therapy are limited.
, it is particularly important to find new and effective GC-targeted biomarkers.
There is growing evidence that long non-coded RNA (lncRNA) is associated with the development of cancer in humans and can play a key role in regulating the development of GC by affecting a variety of cellular functions, including cell proliferation, migration, and stem cell properties.
, however, the level and function of LINC01559 in stomach cancer (GC) has yet to be studied.
the study, based on analysis from the GEPIA (Interactive Analysis of Gene Expression Spectrum) and TCGA (Cancer Genome Map) database, found an increase in the expression level of LINC01559 in GC tissues.
and LINC01559's expression levels in GC cells were lower than those of interstumined stem cells (MSCs).
in-body experiments showed that the expression of silent LINC01559 significantly inhibited the proliferation, migration and stem cell properties of GC cells.
researchers found that LINC01559 is transmitted from MSCs to GC cells through exosomes.
immunofluorescence staining and electroscopy have verified the presence of GC cells and foreign progenitor.
study found that LINC01559 can act as a molecular sponge of miR-1343-3p and raise the expression level of PPK1, thus activating the PI3K/AKT signal path.
addition, LINC01559 is able to collect EZH2 into the initiator region of PTEN, inducing methylation of the PTEN initiator region, which eventually leads to inhibition of PTEN expression.
note that LINC01559 targets PPK1 and PTEN and activates the PI3K/AKT signal path, ultimately facilitating the development of GC.
, the study showed that LINC01559 was able to activate the PI3K/AKT signaling path by raising PPK1 and lowering PTEN expression levels, ultimately promoting the development of GC, suggesting that LINC01559 may be a potential biomarker in the treatment of stomach cancer.
.